stopped tirzepatide NEW: Stopping (Mounjaro) leads patients to gain back the majority of lost weight. - Patients on tirzepatide lost 21% of their body weight in 36 months People Who Stopped Taking the

APPENDIX 1: TABULATED DATA 22

J Am Coll Cardiol 59(3):222231 Lam CS et al (2009) Age-associated increases in pulmonary artery systolic pressure in the general population

GLP-1 weight loss injections are considered safe for most individuals when used under the supervision of a healthcare provider

This further supports the theory that the central and peripheral GLP-1 systems are not only anatomically but also functionally distinct

This means you may hit a weight-loss plateau 46 months into therapy, requiring either maintained semaglutide use to prevent rebound weight gain or a transition to sustainable dietary and exercise habits